Investing in SomaLogic

SomaLogic, Inc. is a privately held biotechnology company with headquarters in Boulder, Colorado.

For all investment questions, please contact us.

A recent presentation outlining our technology, applications and business plan can be downloaded here.

Interested in potential investment opportunities?

SomaLogic Business News

Patrick Terry announced as first Chief Commercial Officer of SomaLogic

SomaLogic announced today that Patrick Terry has joined the company as its first Chief Commercial Officer (CCO). A serial entrepreneur, biomedical science enthusiast and patient advocate, Terry is uniquely qualified to lead the commercialization of SomaLogic’s growing portfolio of protein-based precision health information products.
read more

SomaLogic launches its first SomaSignal™ tests in select medical practices

SomaLogic today launched its first seven SomaSignal™ tests, which are delivered simultaneously to provide actionable health information across a diverse set of human diseases and conditions. Each SomaSignal™ test is built on SomaLogic’s proprietary SomaScan® Platform, which measures thousands of human proteins in a single blood sample. The company expects that eventually there will be hundreds of different SomaSignal™ tests on the SomaScan® Platform.
read more

SomaLogic’s clinical laboratory re-accredited by the College of American Pathologists

SomaLogic announced today that its United States clinical laboratory (CLIA laboratory) has been re-accredited by the College of American Pathologists (CAP). The successful renewal of CAP accreditation is based on the results of a recent on-site inspection designed to ensure the highest laboratory standards.
read more

Agilent and SomaLogic sign agreement for supply of custom microarrays

Agilent Technologies, Inc. (NYSE: A) and SomaLogic, Inc. (a privately held biotechnology company) today announced a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic’s novel SOMAscan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development.
read more

Melody Harris appointed President of SomaLogic

SomaLogic CEO Roy Smythe, M.D. announced today that Melody Harris has been appointed President of SomaLogic. Ms. Harris joined SomaLogic in April 2018 as Chief Legal Officer from Qualcomm Life, a digital health subsidiary of Qualcomm, where she led global and strategic deals with companies such as Novartis, Philips, Abbvie, United Healthcare, Walgreens, and WebMD as Vice President & Chief Counsel.
read more

SomaLogic announces new collaboration with Janssen Research & Development

SomaLogic, Inc. announced today that it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement terms, SomaLogic will analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate protein biomarkers for use by Janssen and SomaLogic in predicting, diagnosing, monitoring, and treating disease.
read more

Proteomic-based diabetes trial launches in UK

SomaLogic is featured prominently in a press release announcing the first patient enrollment in a diabetes prevention study at the Leeds Centre for Personalised Medicine and Health in the UK. The trial uses personalized health insights derived from SomaLogic’s protein measurement technology to advise patients on lifestyle changes to help prevent the onset of type 2 diabetes.
read more

 

For older news and press releases, please visit our archive.